We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
9 result(s) found, displaying 1 to 9
-
Sep-2025Prescription medicine evaluationActive ingredient: mifepristone, misoprostol.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MS-2 Step composite pack [MIFEPRISTONE LINEPHARMA 200 MG TABLET mifepristone 200 mg tablet blister; GyMiso misoprostol 200 microgram tablet blister].
-
Australian public assessment report (AusPar)MS-2 Step (mifepristone & misoprostol composite pack) Product Information and Risk Management Plan changes were approved.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MS-2 Step composite pack [MIFEPRISTONE LINEPHARMA 200 MG TABLET mifepristone 200 mg tablet blister; GyMiso misoprostol 200 microgram tablet blister].
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MS Health Pty Ltd - Syringe, general-purpose.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MS Health Pty Ltd - Cannula, uterine, suction.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MIFEPRISTONE LINEPHARMA 200 MG TABLET mifepristone 200 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for GyMiso misoprostol 200 microgram oral tablet blister pack.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Mifepristone / misoprostol